세계의 피브린 실란트 시장 : 제형별, 용도별, 최종 사용자별 기회 분석 및 산업 예측(2023-2032년)

Fibrin Sealants Market By Dosage Forms, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,131,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,623,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

피브린 실런트(Fibrin Sealants) 시장은 2022년에는 5억 5,000만 달러로 평가되었으며, 2023년부터 2032년까지의 CAGR은 7.8%로 추이하며 성장 할 것으로 예상되며, 2032년에는 11억 3,650만 달러에 이를 것으로 추정됩니다. 피브린 실란트는 주로 지혈제로서 광범위한 수술에 사용되지만 조직 봉합과 상처 치유를 돕기 위해 사용되기도 합니다. 피브린 실란트는 수술 중 공기 및 체액 누출과 같은 수술 합병증을 피하기 위해 사용됩니다. 이러한 실란트는 필름, 분말, 액체 형태로 제공되며 지혈층을 형성하여 대상 부위의 혈액과 공기 누출을 막는 데 도움을 줍니다. 피브린 실란트는 피브리노겐과 트롬빈을 함유하고 있으며 최종 구성이 다릅니다. 이는 결과물인 피브린 응고의 특성에 영향을 미치며 다양한 수술 절차에서 피브린 실란트의 사용에 영향을 미칠 수 있습니다. 피브리노겐 농도가 높은 피브린 실란트는 더 강한 혈전을 생성하는 경향이 있는 반면, 트롬빈 농도가 높은 피브린 실란트는 혈전을 빠르게 형성합니다.

피브린 실란트 시장의 성장을 이끄는 주요 요인으로는 기술 발전, 심장 질환, 암, 허혈성 뇌졸중, 동맥류와 같은 만성 질환의 유병률 증가, 교통 사고 관련 수술의 증가가 피브린 실란트의 높은 채택을 촉진하는 것을 들 수 있습니다. 예를 들어, 세계보건기구에 따르면 심혈관 질환(CVD)은 전 세계 주요 사망 원인으로 매년 약 1,790만 명의 목숨을 앗아가고 있습니다. 2020년에는 전 세계 전체 사망자의 31%에 해당하는 약 1,790만 명이 CVD로 인해 매년 사망하는 것으로 추산됩니다. 예를 들어, 미국 국립보건통계센터에 따르면 매년 미국에서는 약 805,000명의 사람들이 심장마비를 겪습니다. 이로 인해 심장 수술 건수와 피브린 실란트 사용이 증가했습니다.

그러나 피브린 실란트 제품과 관련된 높은 비용과 같은 합병증과 불리한 환급은 시장 성장을 저해 할 것으로 예상됩니다. 반대로 개발도상국의 미충족 의료 수요와 신흥 경제국의 수익성 높은 기회는 향후 전 세계 피브린 실란트 제조업체에 막대한 기회를 창출할 것으로 예상됩니다.

피브린 실란트 시장은 제형, 용도, 최종 사용자, 지역별로 구분됩니다. 제형 기반에서 시장은 액체, 패치, 분말로 분류됩니다. 용도별로는 일반 수술, 심장혈관 수술, 상처 관리, 정형외과, 비뇨기 수술, 안과 등으로 분류됩니다.

최종 사용자별로 병원, 외래수술센터(ASC), 클리닉으로 세분화됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아 태평양(일본, 중국, 호주, 인도, 한국, 기타 아시아 태평양), LAMEA(브라질, 남아프리카공화국, 사우디아라비아 및 기타 LAMEA)로 분석됩니다.

이해관계자를 위한 주요 이점

• 본 보고서는 2022년부터 2032년까지의 피브린 실런트 시장 분석 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공해, 피브린 실런트 시장의 유력한 기회를 특정합니다.
• 시장 성장 촉진 요인, 시장 성장 억제 요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's five forces 분석은 이해관계자가 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급업체의 잠재력을 강조합니다.
• 피브린 실란트 시장의 세분화를 상세하게 분석함으로써 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑됩니다.
• 마켓기업 포지셔닝은 벤치마크를 용이하게 하고 마켓기업의 현재 위치에 대한 명확한 이해를 제공합니다.
• 이 보고서에는 지역별 및 세계 피브린 실런트 시장 동향, 주요 기업, 시장 부문, 응용 분야 및 시장 성장 전략 분석이 포함되어 있습니다.

이 보고서에서 가능한 맞춤설정(추가 비용 및 일정 필요)

• 고객의 관심에 따른 기업 개요 추가
• 국가별 또는 지역별 추가 분석-시장 규모 및 예측
• 평균 판매 가격 분석/프라이스 포인트 분석
• Criss-cross segment 분석-시장 규모 및 예측
• 확장된 기업 개요 목록
• 과거 시장 데이터
• 주요 기업의 상세(소재지, 연락처, 공급업체/벤더 네트워크 등을 포함한 엑셀 형식)
• 글로벌/지역/국가 수준에서 플레이어의 시장 점유율 분석
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향 요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진 요인
    • 노인 인구 증가와 피브린 실란트에 관한 인지도 상승
    • 만성질환 증가와 세계의 수술 건수 증가
  • 억제 요인
    • 피브린 실란트의 막대한 비용 및 대체 제품의 이용 가능성
  • 기회
    • 신흥국의 성장 기회

제4장 피브린 실란트 시장 : 제형별

• 개요
• 액상
  • 액상 피브린 실란트 시장 : 액상 유형별
• 패치
• 파우더

제5장 피브린 실란트 시장 : 용도별

• 개요
• 일반 외과
• 심장혈관 수술
• 상처 관리
• 정형외과
• 비뇨기 수술
• 안과 수술
• 기타

제6장 피브린 실란트 시장 : 최종 사용자별

• 개요
• 병원
• 외래수술센터(ASC)
• 클리닉

제7장 피브린 실란트 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아 태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 남미, 중동 및 아프리카(LAMEA)
  • 브라질
  • 남아프리카공화국
  • 사우디아라비아
  • 기타

제8장 경쟁 구도

• 소개
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제9장 기업 개요

• Baxter International Inc.
• Becton, Dickinson and Company
• Corza Medical
• CSL Behring
• Grifols, SA
• Hemarus Therapeutics Ltd.
• Johnson and Johnson
• Nordson Corporation(Nordson Medical)
• Shanghai Raas Blood Products Co. Ltd
• Vivostat A/S

LYJ

영문 목차

영문목차

The Fibrin Sealants Market was valued for $550.00 million in 2022 and is estimated to reach $1,136.50 million by 2032, exhibiting a CAGR of 7.8% from 2023 to 2032. Fibrin sealants are used in a wide range of surgeries, primarily as hemostatic agents, however, also to assist tissue sealing and wound healing. Fibrin sealants are used during surgeries to avoid surgical complications such as air and fluid leaks. These sealants are available in the form of films, powder, and liquid, and aid by creating a hemostatic layer, which stops blood and air leakage from the targeted area. Fibrin sealants contain fibrinogen and thrombin and differ in their final composition. This affects properties of the resulting fibrin clot and may influence their use in different surgical procedures. Fibrin sealants with high concentrations of fibrinogen tend to produce stronger clots, whereas those containing higher concentrations of thrombin form clots rapidly.

Major factors driving growth of the fibrin sealants market include rise in technological advancements, increase in prevalence rate of chronic diseases, such as heart diseases, cancer, ischemic stroke, aneurysm, and increase in road accidents related surgeries propel high adoption of fibrin sealants. For instance, according to World Health Organization Cardiovascular Diseases (CVDs) are leading cause of death globally, taking an estimated 17.9 million lives each year. It has been estimated in 2020 that around 17.9 million people die each year from CVDs, an estimated 31% of all deaths worldwide. For instance, according to the National Center for Health Statistics, every year, about 805,000 people in the U.S. have a heart attack. This led to increase in number of cardiac surgeries and use of fibrin sealants.

However, unfavorable reimbursements as well as complications such as high costs associated with fibrin sealant products are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for fibrin sealant manufacturers worldwide in the future.

The fibrin sealants market is segmented on the basis of dosage form, application, end user, and region. On the basis of dosage form, the market is classified into liquid, patch, and powder. As per application, it is classified into general surgery, cardiovascular surgery, wound management, orthopedic surgery, urological surgery, ophthalmic surgery, and others.

Depending on end user, it is fragmented into hospitals, ambulatory surgical centers, and clinics. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Baxter International Inc., Becton, Dickinson and Company, Corza Medical, CSL Behring, Grifols, S.A., Hemarus Therapeutics Ltd., Johnson and Johnson, Nordson Corporation (Nordson Medical), Shanghai RAAS Blood Products Co., Ltd., and Vivostat A/S.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the fibrin sealants market analysis from 2022 to 2032 to identify the prevailing fibrin sealants market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the fibrin sealants market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global fibrin sealants market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Average Selling Price Analysis / Price Point Analysis
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• Market share analysis of players at global/region/country level
• SWOT Analysis

Key Market Segments

By Dosage Forms

• Liquid
  • Liquid Type
  • Frozen fibrin sealants
  • Freeze dried fibrin sealants
• Patch
• Powder

By Application

• General Surgery
• Cardiovascular Surgery
• Wound Management
• Orthopedic Surgery
• Urological Surgeries
• Ophthalmic Surgeries
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• Grifols, S.A.
• Baxter International Inc.
• CSL Behring
• Johnson and Johnson
• Hemarus Therapeutics Ltd.
• Nordson Corporation (Nordson Medical)
• Becton, Dickinson and Company
• Vivostat A/S
• Shanghai Raas Blood Products Co. Ltd
• Corza Medical

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in geriatric population and rise in awareness regarding fibrin sealants
    • 3.4.1.2. Growth in the prevalence of chronic diseases and rise in the number of surgical procedures conducted globally
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of fibrin sealants and availability of alternate products
  • 3.4.3. Opportunities
    • 3.4.3.1. Growth opportunities in emerging countries

CHAPTER 4: FIBRIN SEALANTS MARKET, BY DOSAGE FORMS

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Liquid
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Liquid Fibrin Sealants Market by Liquid Type
• 4.3. Patch
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Powder
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: FIBRIN SEALANTS MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. General Surgery
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Cardiovascular Surgery
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Wound Management
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Orthopedic Surgery
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Urological Surgeries
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country
• 5.7. Ophthalmic Surgeries
  • 5.7.1. Key market trends, growth factors and opportunities
  • 5.7.2. Market size and forecast, by region
  • 5.7.3. Market share analysis by country
• 5.8. Others
  • 5.8.1. Key market trends, growth factors and opportunities
  • 5.8.2. Market size and forecast, by region
  • 5.8.3. Market share analysis by country

CHAPTER 6: FIBRIN SEALANTS MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Ambulatory Surgical Centers
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Clinics
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: FIBRIN SEALANTS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Dosage Forms
  • 7.2.3. Market size and forecast, by Application
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Dosage Forms
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Dosage Forms
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Dosage Forms
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Dosage Forms
  • 7.3.3. Market size and forecast, by Application
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Dosage Forms
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Dosage Forms
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Dosage Forms
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Dosage Forms
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Dosage Forms
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Dosage Forms
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Dosage Forms
  • 7.4.3. Market size and forecast, by Application
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Dosage Forms
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Dosage Forms
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Dosage Forms
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Dosage Forms
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Dosage Forms
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Dosage Forms
    • 7.4.5.6.2. Market size and forecast, by Application
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Dosage Forms
  • 7.5.3. Market size and forecast, by Application
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Dosage Forms
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. South Africa
    • 7.5.5.2.1. Market size and forecast, by Dosage Forms
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Saudi Arabia
    • 7.5.5.3.1. Market size and forecast, by Dosage Forms
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Dosage Forms
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Baxter International Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Becton, Dickinson and Company
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Corza Medical
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Key strategic moves and developments
• 9.4. CSL Behring
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
• 9.5. Grifols, S.A.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Hemarus Therapeutics Ltd.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
• 9.7. Johnson and Johnson
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Nordson Corporation (Nordson Medical)
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Shanghai Raas Blood Products Co. Ltd
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
• 9.10. Vivostat A/S
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio

관련자료